Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back


Bulent Ozpolat

University of Texas, USA

Biography

Bulent Ozpolat is an Associate Professor at the Department of Experimental Therapeutics at MD Anderson Cancer Center, Houston, TX, USA. He earned his PhD degree in Immunology from The University of Texas, M.D. Anderson Cancer Center, Houston Graduate School of Biomedical Sciences after getting his MD degree from The University of Dokuz Eylul University, Izmir, Turkey. He completed his graduate and Post-doc Training at the departments of Cancer Biology and Immunotherapy at MD Anderson Cancer Center. His research focuses on identifi cation of novel survival pathways including EF2-Kinase (eEF2K) and autophagy pathways as well as regulation of cell death mechanism such as autophagic and apoptotic cell death; and development of molecularly targeted therapies using tumor-targeting nanotherapeutics (i.e. liposomes, immunoliposomes and metal-magnetic nanoparticles) in aggressive type of solid tumors (i.e. breast, pancreatic and ovarian cancers) and hematological cancers such as leukemia and lymphoma for the delivery of therapeutic cargo including siRNA, microRNA small molecule inhibitors, peptides, proteins, cytokines and anticancer agent. He is a Member of Center for Targeted Therapy and Non-Coding RNA Center and received many research awards in recognition of research excellence. He has published more than 50 papers, 9 book chapters and 12 review articles in peer-reviewed high impact journals and contributed to textbooks.

Abstract

Abstract : Development of novel targeted therapies for triple negative breast cancer: Targeting EF2-kinase

Speaker Presentations

Speaker PPTs Click Here